Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then […]
Pharmaceutical
Rescue Biomedical wins $2.8M grant for nalaxone-releasing implant for opioid overdoses
Rescue Biomedical announced today that it received a $2.8 million grant from the National Institutes of Health for its opioid overdose treatment. West Lafayette, Indiana received a Fast-Track Small Business Innovation Research, or SBIR, grant from the NIH. The company develops technology that detects when a person is overdosing on an opioid and delivers naloxone […]
BD names new president of medication delivery
BD (NYSE:BDX) announced today that it named Eric Borin as its president of medication delivery solutions (MDS). Borin, 55, succeeds Rick Byrd in the role. Byrd recently received a promotion to EVP and president of BD’s interventional segment. As president of medication delivery solutions, Borin will report to Mike Garrison, EVP and president of the […]
This robotic capsule could deliver large-protein drugs like insulin
Researchers at the Massachusetts Institute of Technology (MIT) developed a new drug capsule with a robotic cap for improved drug delivery. Large-protein drugs generally can’t pass through the mucus barrier that lines the digestive tract. Insulin and most other “biologic drugs” with proteins or nucleic acids thus must be injected or administered in a hospital, […]
Pulmatrix completes patient dosing for inhaled migraine treatment
Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment. Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the […]
Vaxxas receives more than $5 million grant for vaccine delivery patch
Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the […]
BD launches next-gen prefillable vaccine syringe
BD (NYSE:BDX) announced today that it launched its next-generation glass prefillable syringe (PFS) for vaccine delivery. Franklin Lakes, New Jersey-based BD’s new Effivax syringe features tightened specifications for processability, cosmetics, contamination and integrity. The company designed it in collaboration with top pharmaceutical firms to meet the evolving needs of vaccine manufacturing. “As biopharmaceutical companies continue […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
FDA approves ‘first-in-market’ autoinjector for treating prolonged seizures
Rafa Laboratories announced today that it received FDA approval for its 10mg Midazolam autoinjector for treating status epilepticus, or prolonged seizures. Jerusalem-based Rafa developed the autoinjector through cooperation with the U.S. Department of Defense’s (D0D) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Rafa’s Midazolam 10mg autoinjector received FDA indication for […]
Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical
Second Sight Medical (Nasdaq:EYES) announced today that it completed its merger with Nano Precision Medical and rebranded. In February, the two companies entered into a definitive agreement under which Nano Precision Medical (NPM) would merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM the surviving company under Second Sight’s ownership. […]
PhysIQ, InCarda Therapeutics to collaborate on AFib treatment tech
PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics. Newark, California–based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases. According to a news release, Syneos Health recommended PhysIQ’s patient monitoring technology to help advance InCarda’s clinical study of InRhythm (orally inhaled flecainide) in patients with AFib. The Phase III […]